KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EBIT (2017 - 2025)

Historic EBIT for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to -$68.9 million.

  • Cardlytics' EBIT rose 5364.8% to -$68.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.0 million, marking a year-over-year increase of 6413.86%. This contributed to the annual value of -$195.5 million for FY2024, which is 4409.89% down from last year.
  • Cardlytics' EBIT amounted to -$68.9 million in Q3 2025, which was up 5364.8% from -$12.8 million recorded in Q2 2025.
  • In the past 5 years, Cardlytics' EBIT registered a high of $35.7 million during Q1 2022, and its lowest value of -$382.6 million during Q4 2022.
  • Its 5-year average for EBIT is -$53.0 million, with a median of -$22.2 million in 2021.
  • Over the last 5 years, Cardlytics' EBIT had its largest YoY gain of 26083.72% in 2022, and its largest YoY loss of 223186.06% in 2022.
  • Quarter analysis of 5 years shows Cardlytics' EBIT stood at -$16.4 million in 2021, then plummeted by 2231.86% to -$382.6 million in 2022, then soared by 73.1% to -$102.9 million in 2023, then skyrocketed by 91.92% to -$8.3 million in 2024, then crashed by 728.17% to -$68.9 million in 2025.
  • Its last three reported values are -$68.9 million in Q3 2025, -$12.8 million for Q2 2025, and -$14.1 million during Q1 2025.